See more : Zhejiang Oceanking Development Co., Ltd. (603213.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Pascal Biosciences Inc. (PSCBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pascal Biosciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ser Educacional S.A. (SEER3.SA) Income Statement Analysis – Financial Results
- Chuo Warehouse Co.,Ltd. (9319.T) Income Statement Analysis – Financial Results
- Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) Income Statement Analysis – Financial Results
- II-VI Incorporated (IIVIP) Income Statement Analysis – Financial Results
- Nestlé S.A. (NSRGY) Income Statement Analysis – Financial Results
Pascal Biosciences Inc. (PSCBF)
About Pascal Biosciences Inc.
Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 670.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.02M | 8.34K | 16.34K | 12.38K | 13.34K |
| Gross Profit | -345.42K | -8.34K | -16.34K | -12.38K | -13.34K |
| Gross Profit Ratio | -51.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.30K | -48.87K | 57.82K | 139.40K | 922.62K |
| General & Administrative | 1.28M | 614.23K | 1.05M | 1.38M | 0.00 |
| Selling & Marketing | 173.31K | -6.32K | 139.42K | 16.67K | 0.00 |
| SG&A | 515.12K | 600.24K | 1.01M | 1.11M | 2.43M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 550.42K | 551.36K | 1.07M | 1.25M | 3.35M |
| Cost & Expenses | 1.57M | 559.70K | 1.08M | 1.26M | 3.37M |
| Interest Income | 0.00 | 1.41K | 0.00 | 412.80 | 17.87K |
| Interest Expense | 28.80K | 3.92K | 5.59K | 6.62K | 8.49K |
| Depreciation & Amortization | 106.71K | 8.34K | 16.34K | 12.38K | 13.34K |
| EBITDA | -789.13K | -497.51K | -1.07M | -1.25M | -3.35M |
| EBITDA Ratio | -117.75% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -895.84K | -559.70K | -1.08M | -1.26M | -3.37M |
| Operating Income Ratio | -133.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 496.90K | 76.99K | -7.88K | 32.55K | -45.64K |
| Income Before Tax | -398.95K | -482.71K | -1.09M | -1.23M | -3.41M |
| Income Before Tax Ratio | -59.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.71 | -1.42K | 1.00 | -410.82 | -17.87K |
| Net Income | -398.95K | -482.71K | -1.09M | -1.23M | -3.41M |
| Net Income Ratio | -59.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.04 | -0.09 | -0.11 | -0.32 |
| EPS Diluted | -0.02 | -0.04 | -0.09 | -0.11 | -0.32 |
| Weighted Avg Shares Out | 23.53M | 13.11M | 12.70M | 11.08M | 10.53M |
| Weighted Avg Shares Out (Dil) | 23.53M | 13.11M | 12.70M | 11.08M | 10.53M |
Pascal Biosciences Awarded NIH Grant For Leukemia Program
Source: https://incomestatements.info
Category: Stock Reports